FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT Trump Budget Proposes Flat $6.2 Billion FDA Budget
02/10/2020
 
 
TXT FDA Monitoring for Shortages Under Virus Plan
02/14/2020
 
 
TXT Foreign ‘Free-Riding’ on U.S. Drug Investment Up: Report
02/13/2020
 
 
TXT Court Changes Drug Country of Origin Determination: Attorney
02/12/2020
 
 
TXT Stop Clinical Trial Advantages in Foreign Countries: Editorial
02/12/2020
 
 
TXT FDA Asks Eisai to Withdraw Belviq from Market
02/13/2020
 
 
TXT Man Sentenced to 7 Years Over Unapproved Drug
02/13/2020
 
 
TXT New 510(k) Review Learning Modules
02/12/2020
 
 
TXT WLF Asks End to California Patent Settlement Law
02/11/2020
 
 
TXT Pharmacogenetic Info Helps Precision Medicine
02/13/2020
 
 
TXT FTC Sues 2 Companies Over Joint Pain Products
02/12/2020
 
 
TXT Latest Federal Register Notices
02/17/2020
 
 
TXT Product Approval Summaries
02/17/2020
 
 
TXT Since Our Last Issue ...
02/17/2020
 
 
TXT CDRH Workshop on Computational Modeling Practices
02/14/2020
 
 
TXT FDA Docket Seeks Data/Info on Vaping Injuries
02/14/2020
 
 
TXT Sellas Nelipepimut-S Phase 3 Study in Breast Cancer
02/14/2020
 
 
TXT Lupin Pithampur Inspection Has 2 Observations
02/12/2020
 
 
TXT CDER Launches Controlled Substances Program
02/12/2020
 
 
TXT Workshop on DNA-based Cancer Screening Tests
02/12/2020
 
 
TXT Medtronic MiniMed Pump Recall is Class 1
02/12/2020
 
 
TXT Peripheral Vascular Atherectomy Device Guidance
02/12/2020
 
 
TXT 2 Annual Pharmacology Reports Available
02/12/2020
 
 
TXT OPQ Looks at Five Years of Success
02/11/2020
 
 
TXT Erectile Dysfunction Drug Notice Sought
02/11/2020
 
 
TXT SCA Pharmaceuticals FDA-483
02/11/2020
 
 
TXT Sentinel Surveillance System Workshop in April
02/11/2020
 
 
TXT Latest FDA Warning Letter
02/11/2020
 
 
TXT FDA, BrainStorm Cell Agree on Potential NurOwn Pathway
02/11/2020
 
 
TXT FDA Phone Safety Review: No Adverse Health Effects
02/10/2020
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving